Literature DB >> 26403249

Exploratory study of total and free prednisolone plasma exposure and cushingoid appearance, quality of life and biochemical toxicity in adult male kidney transplant recipients.

Troels K Bergmann1,2, Nicole M Isbel3, Remo Ostini4, Katherine A Barraclough5, Scott B Campbell3, Brett C McWhinney6, Warrick J Inder7,8, Anthony Russell7,8, Christine E Staatz9.   

Abstract

BACKGROUND AND
OBJECTIVE: Long-term adverse effects of oral glucocorticoids are frequent and serious. Large between-patient variability in the pharmacokinetics of prednisolone might explain why drug dose is a poor predictor of drug-related toxicity. The aim of the study was to investigate relationships between prednisolone exposure and adverse effects.
METHODS: Male kidney transplant recipients were recruited for serial blood sampling and assessment of glucocorticoid-related adverse effects including dyslipidaemia, abnormal body fat distribution, Cushingoid appearance and impaired quality of life. Total and free prednisolone plasma concentrations were determined using ultra-high-performance liquid chromatography with tandem mass spectrometric detection. Prednisolone exposure was estimated using a limited sampling strategy.
RESULTS: Fifty-six patients were recruited. Patients had a mean age of 54 years and median time post-transplantation of 75 months. Median prednisolone dose was 5 mg. Mean area under the plasma concentration-time curve was 2390 nmol h/L (±580) (SD) and 175 nmol h/L (±78) for total and free prednisolone, respectively. Waist to upper arm circumference ratio was positively associated with free prednisolone plasma exposure with a Spearman correlation coefficient of 0.30 (p value 0.02). The correlation coefficient was 0.24 (p value 0.08) for neck to upper arm circumference ratio and free prednisolone plasma exposure. The clinical Cushingoid phenotype as determined by the Visual Assessment of Cushing's Severity (VACS) score was associated with a reduced score relating to physical functioning on the SF-12, but there was no significant relationship between free prednisolone plasma exposure and quality-of-life scores. Lipid levels and haemoglobin A1c (HbA1c) were not associated with total or free prednisolone exposure.
CONCLUSIONS: There is a positive correlation between free prednisolone plasma exposure and waist to upper arm circumference ratio in adult male kidney transplant recipients on low maintenance prednisolone doses. There is no significant association between total or free prednisolone plasma exposure and plasma glucose and lipid levels in the low prednisolone dose range.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26403249     DOI: 10.1007/s40261-015-0334-2

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  28 in total

1.  A clinical index for rating severity in Cushing's syndrome.

Authors:  N Sonino; M Boscaro; F Fallo; G A Fava
Journal:  Psychother Psychosom       Date:  2000 Jul-Aug       Impact factor: 17.659

2.  The dose-dependent systemic availability of prednisone: one reason for the reduced biological effect of alternate-day prednisone.

Authors:  F J Frey; M K Rüegsegger; B M Frey
Journal:  Br J Clin Pharmacol       Date:  1986-02       Impact factor: 4.335

3.  Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients.

Authors:  F J Frey; W J Amend; F Lozada; B M Frey; N H Holford; L Z Benet
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

4.  Renal transplantation without steroids.

Authors:  J R Salaman; C A Gomes Da Costa; P J Griffin
Journal:  J Pediatr       Date:  1987-12       Impact factor: 4.406

Review 5.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

6.  Therapeutic drug monitoring of prednisolone after lung transplantation.

Authors:  Judith M Morton; Sharon Williamson; Laurie M Kear; Brett C McWhinney; Julia Potter; Allan R Glanville
Journal:  J Heart Lung Transplant       Date:  2006-04-11       Impact factor: 10.247

7.  Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population.

Authors:  Julia M Potter; Brett C McWhinney; Lee Sampson; Peter E Hickman
Journal:  Ther Drug Monit       Date:  2004-08       Impact factor: 3.681

Review 8.  11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.

Authors:  Jeremy W Tomlinson; Elizabeth A Walker; Iwona J Bujalska; Nicole Draper; Gareth G Lavery; Mark S Cooper; Martin Hewison; Paul M Stewart
Journal:  Endocr Rev       Date:  2004-10       Impact factor: 19.871

9.  Prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients.

Authors:  H Bergrem; J Jervell; A Flatmark
Journal:  Kidney Int       Date:  1985-02       Impact factor: 10.612

10.  Prednisolone disposition in cushingoid and noncushingoid kidney transplant patients.

Authors:  J G Gambertoglio; F Vincenti; N J Feduska; J Birnbaum; O Salvatierra; W J Amend
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

View more
  1 in total

1.  A randomised controlled unblinded multicentre non-inferiority trial with activated vitamin D and prednisolone treatment in patients with minimal change nephropathy (ADAPTinMCN).

Authors:  Tilde Kristensen; Henrik Birn; Per Ivarsen
Journal:  Trials       Date:  2021-07-12       Impact factor: 2.279

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.